Semaglutide in people with obesity: boosts wellbeing and ability to perform daily physical activities (2)

CET- Comunicado -
";ultimaHoraHtml += "
" + json.lead + "";}ultimaHoraHtml += "";
document.getElementById("urgente").innerHTML = ultimaHoraHtml;
}
}
});
BAGSVÆRD, Denmark, May 13, 2021 /PRNewswire/ -- Novo Nordisk today announced new results from the STEP phase 3a clinical trial programme, demonstrating potential benefits beyond weight loss for people with obesity being treated with semaglutide 2.4 mg. The trial showed that treatment with once-weekly semaglutide 2.4 mg led to significant improvements in physical functioning, such as climbing stairs and tying your shoes, and beneficial effects on weight related and health related quality of life scores (HRQoL) compared to placebo.* Following the 68-week treatment period, more than half of participants had improved quality of life scores, indicating better physical function and improved psychological wellbeing.

Related Keywords

Denmark ,Canada ,Toronto ,Ontario ,Sean Wharton ,Prnewswire Novo Nordisk ,Martin Holst Lange ,Linkedin ,Twitter ,Drug Administration ,Development At Novo Nordisk ,Youtube ,Facebook ,European Medicines Agency ,European Congress On Obesity ,Novo Nordisk ,European Congress ,Wharton Medical Clinic ,Semaglutide Treatment Effect ,Life Lite Clinical Trials Version ,Short Form ,டென்மார்க் ,கனடா ,டொராண்டோ ,ஆஂடேரியொ ,சீன் வார்டன் ,மார்டின் ஹோல்ஸ்ட் லாங்கே ,சென்டர் ,ட்விட்டர் ,வலைஒளி ,முகநூல் ,ஐரோப்பிய காங்கிரஸ் ஆன் உடல் பருமன் ,ஐரோப்பிய காங்கிரஸ் ,வார்டன் மருத்துவ சிகிச்சையகம் ,குறுகிய வடிவம் ,